CAJ | 학술논문

目的探讨厄洛替尼联合放疗治疗老年食管癌的疗效和安全性.方法 2007年12月26日至2011年2月14日温州医学院附属第一医院符合条件的老年食管癌患者给予60 Gy/30 F放疗并同步厄洛替尼150 mg/d.观察生存情况和毒性反应,用SPSS 17.0统计软件包分析结果.结果 33例患者人组.1、2年生存率分别为66.3％、49.7％,中位生存期(16.3±8.6)个月(95％ CI0.0～33.3),中位无疾病进展时间(16.7±7.1)个月(95％ CI2.9～30.5).1、2年局部控制率为73.3％、54.9％.治疗主要毒性反应为放射性食管炎,肺炎,皮疹,多为1～2级.结论老年食管癌患者厄洛替尼联合化疗方案治疗显示了满意的疗效,安全可行.此Ⅱ期临床研究结果尚需更大样本的临床研究证实.
목적 탐토액락체니연합방료치료노년식관암적료효화안전성.방법 2007년12월26일지2011년2월14일온주의학원부속제일의원부합조건적노년식관암환자급여60 Gy/30 F방료병동보액락체니150 mg/d.관찰생존정황화독성반응,용SPSS 17.0통계연건포분석결과.결과 33례환자인조.1、2년생존솔분별위66.3％、49.7％,중위생존기(16.3±8.6)개월(95％ CI0.0～33.3),중위무질병진전시간(16.7±7.1)개월(95％ CI2.9～30.5).1、2년국부공제솔위73.3％、54.9％.치료주요독성반응위방사성식관염,폐염,피진,다위1～2급.결론 노년식관암환자액락체니연합화료방안치료현시료만의적료효,안전가행.차Ⅱ기림상연구결과상수경대양본적림상연구증실.
Objective To evaluate the safety and efficacy of radiation plus erlotinib in patients with esophageal cancer older than 70 years.Methods Radiotherapy was prescribed at a daily fraction of 2.0 Gy up to a total dose of 60 Gy over 6 weeks.Concurrent erlotinib was administrated at a dose of 150 mg daily at days 1 - 42.Acute toxicities were assessed by the criteria of Radiation Therapy Oncology Group ( RTOG )and National Cancer Institute (NCI).The results were analyzed by the software SPSS 17.0.Results A total of 33 patients were enrolled.The median survival time was 16.3 ± 8.6 months(95％ CI 0.0 - 33.3 ) and the 1-and 2-year overall survival rates were 66.3％ and 49.7％ respectively.The media progression-free survival was 16.7 ±7.1 months(95％ CI 2.9 - 30.5) and the 1-and 2-year local control rates 73.3％ and 54.9％respectively.Most toxicities were of grade 1-2 and manageable.Conclusion The combined regimen of radiation and erlotinib is effective and safe in elder patients aged ＞70 years with esophageal cancer.However the results of our study should be confirmed in randomized controlled trials of a larger sample size.